Outcomes with CPX-351 versus 7+3 by baseline bone marrow blast percentage in older adults with newly diagnosed, high-risk/secondary aml: Exploratory analysis of a phase 3 study

Category Primary study
JournalHemaSphere
Year 2019
This article has no abstract
Epistemonikos ID: 4d29cd6b67f01d172f15e52fa689f268c718fb0d
First added on: Feb 11, 2025